Fas/APO-1/CD95 in health and autoimmune disease: Thymic and peripheral aspects

Seminars in Immunology

Volumn 10, Issue 6, 1998, Pages 449-456

  Moulian, Nathalie ^b   Berrih Aknin, Sonia ^a  

^a CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^b NONE

Author keywords

Apoptosis; Autoimmune disease; Fas (APO 1 CD95); Lymphocyte; Thymus

Indexed keywords

FAS ANTIGEN; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIGEN EXPRESSION; APOPTOSIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL DEATH; CELL MEDIATED CYTOTOXICITY; CELL SURVIVAL; ENCEPHALITIS; HASHIMOTO DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE ACTIVATION; MYASTHENIA GRAVIS; NONHUMAN; REVIEW; SJOEGREN SYNDROME; T LYMPHOCYTE; THYMOCYTE; THYMUS;

EID: 0032387847     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1006/smim.1998.0155     Document Type: Article

References (71)

1. 1. Nagata S, Goldstein P (1995) The Fas death factor. Science 267:1449-1456
2. 2. Yuan J (1997) Transducing signals of life and death. Curr Opin Cell Biol 9:247-251
3. 3. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME, Dixit VM (1996) FLICE, a novel, FADD homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85:817-827
4. 4. Boldin MP, Goncharov TM, Goltsev YV, Wallach D (1996) Involvement of MACH, a novel MORT1/FADD interacting protease, in Fas/APO-1 and TNF receptor-induced cell death. Cell 85:803-815
5. 5. Hirata H, Takahashi A, Kobayashi S, Yonehara S, Sawai H, Okazaki T, Yamamoto K, Sasada M (1998) Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. J Exp Med 187:587-600
6. 6. Sato T, Irie S, Kitada S, Reed JC (1995) FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 268:411-415
7. 7. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schröter M, Burns K, Mattman C, Rimoldi D, French LE, Tschopp J (1997) Inhibition of death receptor signals by cellular FLIP. Nature 388:190-195
8. 8. Hitoshi Y, Lorens J, Kitada SI, Fisher J, LaBarge M, Ring HZ, Francke U, Reed JC, Kinoshita S, Nolan GP (1998) Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells. Immunity 8:461-471
9. 9. Suda T, Tanaka M, Miwa K, Nagata S (1996) Apoptosis of mouse naive T cells induced by recombinant soluble Fas ligand and activation-induced resistance to Fas ligand. J Immunol 157:3918-3924
10. 10. Tanaka M, Itai T, Adachi M, Nagata S (1998) Downregulation of Fas ligand by shedding. Nat Med 4:31-36
11. 11. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S (1997) Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 186:2045-2050
12. 12. Miyawaki Y, Uehara T, Nibu R, Tsuji T, Yachie A, Yonehara S, Taniguchi N (1992) Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J Immunol 149:3753-3758
13. 13. Kägi D, Vignaux F, Ledermann B, Bürki K, Depraetere V, Nagata S, Hengartner H, Goldstein P (1994) Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265:528-530
14. +-independent T cell-mediated cytotoxicity. J Exp Med 177:195-200
15. 15. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA (1995) Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189-1191
16. 16. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC (1995) A role for CD95 ligand in preventing graft rejection. Nature 377:630-632
17. 17. Uckan D, Steele A, Cherry A, Wang BY, Chamizo W, Koutsonikolis A, Gilbert-Barness E, Good RA (1997) Trophoblasts express Fas ligand: a proposed mechanism for immune privilege in placenta and maternal invasion. Mol Hum Reprod 3:655-662
18. 18. Strand S, Hofmann WJ, Hug H, Müller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR (1996) Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion. Nat Med 2:1361-1366
19. 19. Dhein J, Walczak H, Bäumler C, Debatin KM, Krammer PH (1995) Autocrine T-cell suicide mediated by APO-1 (Fas/CD95). Nature 373:438-441
20. 20. Brunner T, Mogil RG, LaFace D, Yoo NJ, Mahboubi A, Echeverri F, Martin SJ, Force WR, Lynch DH, Care CH, Green DR (1995) Cell autonomous Fas (CD95)/Fas-ligand interaction mediate activation-induced apoptosis in T-cell hybridomas. Nature 373:441-444
21. 21. Ju ST, Panka DJ, Cui H, Ettinger R, El-Khatib M, Sherr DH, Stanger BZ, Marshak-Rothstein A (1995) Fas (CD95)/FasL interactions required for programmed cell death after activation. Nature 373:444-448
22. 22. Spaner D, Raju K, Radvanyi L, Lin Y, Miller RG (1998) A role for perform in activation-induced cell death. J Immunol 160:2655-2664
23. 23. Alderson MR, Armitage RJ, Marakovsky E, Tough TW, Roux E, Scooley K, Ramsdelll F, Lynch DH (1993) Fas transduces activation signals in normal human T lymphocytes. J Exp Med 178:2231-2235
24. 24. Abreu-Martin MT, Vidrich A, Lynch DH, Targan SR (1995) Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-a and ligation of Fas antigen. J Immunol 155:4147-4154
25. 25. Lau TL, Yu M, Fontana A, Stoeckert CJ (1996) Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 273:109-112
26. 26. Kang SM, Schneider DB, Lin Z, Hanahan D, Dichek DA, Stock PG, Baekkeskov S (1997) Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets for rapid destruction. Nat Med 3:738-743
27. 27. Strasser A, O'Connor L (1998) Fas ligand-caught between Scylla and Charybdis. Nat Med 4:21-22
28. + thymocytes by the anti-Fas antibody. J Exp Med 181:485-491
29. 29. Fisher GH, Lenardo MJ, Zuniga-Pflücker JC (996) Synergy between T cell receptor and Fas (CD95/APO-1) signaling in mouse thymocyte death. Cell Immunol 169:99-106
30. 30. Zhou T, Fleck M, Müeller-Ladner U, Yang P, Wang Z, Gay S, Matsumoto S, Mountz JD (1997) Kinetics of Fas-induced apoptosis in thymic organ culture. J Clin Immunol 17:74-84
31. 31. Nishimura Y, Hirabayashi Y, Matsuzaki Y, Musette P, Ishii A, Nakauchi H, Inoue T, Yonehara S (1997) In vivo analysis of Fas antigen-mediated apoptosis: effects of agonistic anti-mouse Fas mAb on thymus, spleen and liver. Int Immunol 9:307-316
32. 32. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S (1992) Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314-317
33. 33. Singer GG, Abbas AK (1994) The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1:365-371
34. 34. Sytwu HK, Liblau R, McDevitt HO (1996) The roles of Fas/APO-1 (CD95) and TNF in antigen-induced programmed cell death in T cell receptor transgenic mice. Immunity 5:17-30
35. 35. Adachi M, Suematsu S, Suda T, Watanabe D, Fukuyama H, Ogasawara J, Tanaka T, Yoshida N, Nagata S (1996) Enhanced and accelerated lymphoproliferation in Fas-null mice. Proc Natl Acad Sci USA 93:2131-2136
36. 36. Castro JE, Listman JA, Jacobson BA, Wang Y, Lopez PA, Ju S, Finn PW, Perkins DL (1996) Fas modulation of apoptosis during negative selection of thymocytes. Immunity 5:617-627
37. 37. Kishimoto H, Sprent J (1997) Negative selection in the thymus includes semimature T cells. J Exp Med 185:263-272
38. 38. Kishimoto H, Surh CD, Sprent J (1998) A role for Fas in negaative selection of thymocytes in vivo. J Exp Med 187:1427-1438
39. 39. Debatin KM, Süss D, Krammer PH (1994) Differential expression of APO-1 on human thymocytes: implications for negative selection? Eur J Immunol 24:753-758
40. 40. Yonehara S, Nishimura Y, Kishil S, Yonehara M, Takazawa K, Tamatani T, Ishii A (1994) Involvement of apoptosis antigen Fas in clonal deletion of human thymocytes. Int Immunol 6:1849-1856
41. 41. Moulian N, Bidault J, Truffault F, Yamamoto AM, Levasseur P, Berrih-Aknin S (1997) Thymocyte Fas expression is dysregulated in Myasthenia gravis patients with anti-acetylcholine receptor antibody. Blood 89:3287-3295
42. 42. Moulian N, Bidault J, Planché C, Berrih-Aknin S (1998) Two signaling pathways can increase Fas expression in human thymocytes. Blood 92:1297-1307
43. 43. Fisher GH, Rosenberg FJ, Staus SE, Dale JK, Middelton LA, Lin AY, Strober W, Lenardo MJ, Puck JM (1995) Dominant interfering Fas gene mutations impair apoptosis in a human lymphoproliferative syndrome. Cell 81:935-946
44. 44. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IAG, Debatin KM, Fisher A, de Villartay JP (1995) Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268:1347-1349
45. 45. Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB (1996) Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 335:1643-1649
46. 46. Pensati L, Costanzo A, Ianni A, Accapezzato D, Ioro R, Natoli G, Nisini R, Almerighi C, Balsano C, Vajro P, Vegnente A, Levrero M (1997) Fas/APO1 mutations and autoimmune lymphoproliferative syndrome in a patient with type 2 autoimmune hepatitis. Gastroenterology 113:1384-1389
47. 47. Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD (1996) Fas ligand in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 98:1107-1113
48. 48. Waldner H, Sobel RA, Howard E, Kuchroo VK (1997) Fas-and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis. J Immunol 159:3100-3103
49. 49. Dowling P, Shang G, Raval S, Menonna J, Cook S, Husar W (1996) Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J Exp Med 184:1513-1518
50. 50. D'Souza SD, Bonetti B, Balasingam V, Cashman NR, Barker PA, Troutt AB, Raine CS, Antel JP (1996) Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J Exp Med 184:2361-2370
51. 51. Itoh N, Imagawa A, Hanafusa T, Waguri M, Yamamoto K, Iwahashi H, Moriwaki M, Nakajima H, Miyagwa J, Namba M, Makino S, Nagata S, Kono N, Matsuzawa Y (1997) Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice. J Exp Med 186:613-618
52. 52. Chervonsky AV, Wang Y, Susan Wong F, Visintin I, Flavell RA, Janeway CA, Matis LA (1997) The role of Fas in autoimmune diabetes. Cell 89:17-24
53. 53. Stassi G, De Maria R, Trucco G, Rudert W, Testi R, Galluzo A, Giordano C, Trucco M (1997) Nitric oxide primes pancreatic β cells for Fas-mediated destruction in insulin-dependent diabetes mellitus. J Exp Med 186:1193-1200
54. 54. Giordano C, Stassi G, De Maria R, Todaro M, Richiusa P, Papoff G, Ruberti G, Bagnasco M, Testi R, Galluzo A (1997) Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 275:960-963
55. 55. Kong L, Ogawa N, Nakabayashi T, Liu GT, D'Souza E, McGuff HS, Guerrero D, Talal N, Dang H (1997) Fas and its ligand expression in the salivary glands of patients with primary Sjogren's syndrome. Arthritis Rheum 40:87-97
56. 56. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD (1995) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759-1761
57. 57. Goel N, Ulrich DT, StClair EW, Fleming JA, Lynch DH, Seldin MF (1995) Lack of correlation between serum soluble Fas/Apo-1 levels and autoimmune disease. Arthritis Rheum 38:1738-1743
58. 58. Knipping E, Krammer PH, Onel KB, Lehman TJA, Mysler E, Elkon KB (1995) Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum 38:1735-1737
59. 59. Bansil S, Holtz CR, Cook SD Rohowsky Kochan C (1997) Serum sAPO-1/Fas levels in multiple sclerosis. Acta Neurol Scand 95:208-210
60. 60. Shimaoka Y, Hidaka Y, Okumura M, Takeoka K, Tada H, Amino N (1998) Serum concentration of soluble Fas in patients with autoimmune thyroid diseases. Thyroid 8:43-47
61. 61. Mysler E, Bini P, Drappa J, Ramos P, Friedman SM, Krammer PH, Elkon KB (1994) The apoptosis-1/Fas protein in human systemic lupus erythematosus. J Clin Invest 93:1029-1034
62. 62. Ohsako S, Hara M, Harigai M, Fukasawa C, Kashiwasaki S (1994) Expression and function of Fas antigen and bcl-2 in human systemic erythematosus lymphocytes. Clin Immunol Immunopathol 73:109-114
63. 63. Ichikawa H, Ota K, Iwata M (1996) Increased Fas antigen on T cells in multiple sclerosis. J Neuroimmunol 71:125-129
64. 64. Berrih-Aknin S, Morel E, Raimond F, Safar D, Gaud C, Binet JP, Levasseur P, Bach JF (1987) The role of the thymus in Myasthenia Gravis. Immunohistological and immunological studies in 115 cases. Ann NY Acad Sci 505:50-70
65. 65. Mulder DG, Graves M, Herrmann C (1989) Thymectomy for myasthenia gravis: recent observations and comparisons with past experience. Ann Thorac Surg 48:551-556
66. 66. Lindstrom JM, Seybold ML, Lennon VA, Whittingham S, Duane DD (1976) Antibody to acetylcholine receptor in Myasthenia Gravis: prevalence, clinical correlates, and diagnostic value. Neurology (Minneap) 26:1054-1069
67. 67. Moulian N, Wakkach A, Guyon T, Poëa S, Aïssaoui A, Levasseur P, Cohen-Kaminsky S, Berrih-Aknin S (1998) Respective role of thymus and muscle in autoimmune Myasthenia gravis. Ann NY Acad Sci 841:397-406
68. 68. Melms AS, Chreste BCG, Schalke H, Wekerle H, Mauron A, Ballivet M, Barkas T (1989) Autoimmune T lymphocytes in myasthenia gravis: determination of target epitopes using T lines and recombinant products of the mouse nicotinic acetylcholine receptor gene. J Clin Invest 83:785-790
69. 69. Sommer N, Willcox N, Harcourt GC, Newsom-Davis J (1990). Myasthenic thymus and thymoma are selectively enriched in acetylcholine receptor-reactive T cells. Ann Neurol 28: 312-319
70. 70. Willcox N, Newsom-Davis J, Calder LR (1984) Cell types for anti-acetylcholine receptor antibody by cultured thymocytes and blood lymphocytes in myasthenia gravis. Clin Exp Immunol 58:97-106
71. 71. Leprince C, Cohen-Kaminsky S, Berrih-Aknin S, Vernet der Garabedian B, Treton D, Galanaud P, Richard Y (1990) Thymic B cells from Myasthenia Gravis (MG) patients are activated B cells: phenotypic and functional analysis. J Immunol 145:2115-2122